Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 9:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Loss of Vision Clear all
Completed Not applicable Interventional

Timing of Low Vision Rehabilitation in Anti- Vascular Endothelial Growth Factor (VEGF) Therapy

NCT03065907
View directory record Official record
Conditions
Low Vision, Neovascular Age-related Macular Degeneration
Interventions
Vision rehabilitation
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
50 Years to 105 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 15, 2019 · Synced Jun 10, 2026, 9:20 PM EDT
Completed No phase listed Observational Results available

Chart Review: Drug Utilization Study in Participants Who Received Ozurdex™ (Dexamethasone Intravitreal Implant) 0.7 mg Injections for Visual Impairment Due to Diabetic Macular Edema (DME)

NCT03889444
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Dexamethasone intravitreal implant
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Jun 21, 2020 · Synced Jun 10, 2026, 9:20 PM EDT
Completed Phase 3 Interventional Results available

Efficacy Study of GS010 for the Treatment of Vision Loss up to 6 Months From Onset in LHON Due to the ND4 Mutation

NCT02652767
View directory record Official record
Conditions
Optic, Atrophy, Hereditary, Leber
Interventions
GS010, Sham Intravitreal Injection
Biological · Device
Lead sponsor
GenSight Biologics
Industry
Eligibility
15 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
Los Angeles, California • Atlanta, Georgia • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Jun 10, 2026, 9:20 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Determine the Long-Term Safety, Tolerability and Biological Activity of SAR421869 in Patients With Usher Syndrome Type 1B

NCT02065011
View directory record Official record
Conditions
Usher's Syndrome
Interventions
Blood draw for the laboratory assessment
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2031
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Jun 10, 2026, 9:20 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Virtual Reality Platform Simulating Visual Impairment for Testing of Electronic Travel Aids and Performing Orientation and Mobility Training

NCT05135195
View directory record Official record
Conditions
Visual Impairment, Age-Related Macular Degeneration, Diabetic Retinopathy, Glaucoma
Interventions
In-House Developed VR Platform - AMD, DR, Glaucoma, In-House Developed VR Platform - Glaucoma
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 80 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 2, 2023 · Synced Jun 10, 2026, 9:20 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Idiopathic Intracranial Hypertension Treatment Trial

NCT01003639
View directory record Official record
Conditions
Idiopathic Intracranial Hypertension
Interventions
Acetazolamide, Placebo, Formal weight loss counselling program
Drug · Behavioral
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
18 Years to 60 Years
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
39
States / cities
Birmingham, Alabama • Los Angeles, California • Waterbury, Connecticut + 31 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2018 · Synced Jun 10, 2026, 9:20 PM EDT
Recruiting Phase 3 Interventional

Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of VA Loss Due to Radiation Retinopathy

NCT05844982
View directory record Official record
Conditions
Radiation Retinopathy, Visual Impairment
Interventions
Faricimab, fluocinolone acetonide
Drug
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
23
States / cities
Palo Alto, California • Manchester, Connecticut • Tampa, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Jun 10, 2026, 9:20 PM EDT
Completed Not applicable Interventional

Digital Ocular Fundus Photography in the Emergency Department: A New Application for Telemedicine?

NCT00873613
View directory record Official record
Conditions
Headache, Acute, Focal Neurologic Disease, Severely Elevated Blood Pressure, Acute Visual Loss
Interventions
Use of Non-dilated retinal photography
Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
705 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 7, 2013 · Synced Jun 10, 2026, 9:20 PM EDT
Recruiting Phase 1 Interventional

Socially Assistive Robots to Enhance Magnification Device Use for Reading

NCT04190134
View directory record Official record
Conditions
Low Vision
Interventions
Socially Assistive Robot for Low Vision Rehabilitation
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 18, 2024 · Synced Jun 10, 2026, 9:20 PM EDT
Completed Phase 1 Interventional

A Phase I Single Ascending Dose Study of the Intravitreal Plasma Kallikrein Inhibitor KVD001 in Subjects With DME

NCT02193113
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
KVD001 Injection
Drug
Lead sponsor
KalVista Pharmaceuticals, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
5
States / cities
Beverly Hills, California • Indianapolis, Indiana • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced Jun 10, 2026, 9:20 PM EDT
Completed Phase 3 Interventional Results available

A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion)

NCT05850520
View directory record Official record
Conditions
Macular Edema Secondary to Retinal Vein Occlusion
Interventions
Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose, Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg, Sham, Fluorescein
Drug · Diagnostic Test
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
892 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
53
States / cities
Fullerton, California • Long Beach, California • Mountain View, California + 48 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Jun 10, 2026, 9:20 PM EDT
Completed Not applicable Interventional

Diabetic Retinopathy Tethered Augmented Reality With Eye4 Study

NCT05491746
View directory record Official record
Conditions
Diabetic Retinopathy, Low Vision
Interventions
Eye4, Placebo
Device · Other
Lead sponsor
Eyedaptic
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Laguna Hills, California
Source: ClinicalTrials.gov public record
Updated Feb 14, 2023 · Synced Jun 10, 2026, 9:20 PM EDT
Terminated Not applicable Interventional Results available

Optic-to-Audio Device in a Pediatric Cohort With CLN3-related Conditions or Low Vision

NCT04974307
View directory record Official record
Conditions
CLN3-related Disorders, Non-CLN3 Related Low Vision
Interventions
OrCam MyEye 2
Device
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
6 Years to 18 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 22, 2024 · Synced Jun 10, 2026, 9:20 PM EDT
Completed Not applicable Interventional Results available

Visuomotor Rehabilitation Training for Manual Task Deficits From Macular Scotomas

NCT01691027
View directory record Official record
Conditions
Scotoma, Central, Central Visual Impairment
Interventions
Visuo-motor training
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
55 Years to 95 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Jun 10, 2026, 9:20 PM EDT
Completed Phase 1 Interventional

EYE001 to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome

NCT00056199
View directory record Official record
Conditions
Hippel-Lindau Disease
Interventions
EYE001
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jun 10, 2026, 9:20 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

The Effects of Concussion on Gait and Posture in Individuals With Peripheral Vision Loss

NCT05948501
View directory record Official record
Conditions
Concussion, Eye
Interventions
Not listed
Lead sponsor
Gaylord Hospital, Inc
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
2
States / cities
New Haven, Connecticut • Wallingford, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 21, 2025 · Synced Jun 10, 2026, 9:20 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Yoga for Persons With Severe Visual Impairment

NCT01366677
View directory record Official record
Conditions
Sleep Disturbance, Stress, Anxiety, Depression, Balance Impairment
Interventions
Yoga Intervention
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 85 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 25, 2014 · Synced Jun 10, 2026, 9:20 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Study to See How Low Level Laser Light Affects Subcutaneous Fat Around the Hips and Waist

NCT01292564
View directory record Official record
Conditions
Weight Loss
Interventions
Erchonia MLS, Placebo Laser
Device
Lead sponsor
Erchonia Corporation
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Fox River Grove, Illinois
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Jun 10, 2026, 9:20 PM EDT
Recruiting Phase 3 Interventional

Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research

NCT07623668
View directory record Official record
Conditions
Optic Neuritis
Interventions
Privosegtor, Methylprednisolone, Placebo
Drug · Other
Lead sponsor
Oculis
Industry
Eligibility
18 Years to 50 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Jun 10, 2026, 9:20 PM EDT
Completed Phase 2 Interventional Results available

Low Vision Intervention Trial II (LOVIT II)

NCT00958360
View directory record Official record
Conditions
Central Vision Loss From Macular Diseases
Interventions
Interdisciplinary Low Vision Service, Basic Low Vision Service
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
7
States / cities
Hines, Illinois • Baltimore, Maryland • Cincinnati, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2016 · Synced Jun 10, 2026, 9:20 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO)

NCT06789445
View directory record Official record
Conditions
Primary Photoreceptor Disease, Retinitis Pigmentosa (RP), Usher Syndrome, Inherited Retinal Disease (IRD), Rod-Cone Dystrophy, Rod-Cone Disease, Retinal Degeneration, Cone-Rod Disease (C-RD), Cone-Rod Dystrophy
Interventions
OpCT-001
Biological
Lead sponsor
BlueRock Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
4
States / cities
Miami, Florida • Philadelphia, Pennsylvania • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Jun 10, 2026, 9:20 PM EDT
Completed Phase 3 Interventional Results available

Low Vision Depression Prevention Trial for Age Related Macular Degeneration

NCT00769015
View directory record Official record
Conditions
Age-related Macular Degeneration, Depression
Interventions
BA-LVR, ST-LVR
Behavioral
Lead sponsor
Thomas Jefferson University
Other
Eligibility
65 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 19, 2014 · Synced Jun 10, 2026, 9:20 PM EDT
Terminated Not applicable Interventional Results available

Spatial Cognitive Training

NCT03423654
View directory record Official record
Conditions
Blind
Interventions
Spatial Training, Letter number matching
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
50 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Atlanta, Georgia • Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 17, 2020 · Synced Jun 10, 2026, 9:20 PM EDT
Active, not recruiting Not applicable Interventional

Visual Rehabilitation After Occipital Stroke

NCT04798924
View directory record Official record
Conditions
Stroke, Ischemic, Quadrantanopia, Vision Loss Partial, Visual Field Defect, Peripheral, Peripheral Visual Field Defect of Both Eyes, Peripheral Visual Field Defect, Hemianopsia, Hemianopia, Homonymous Hemianopia, Homonymous Hemianopsia, Visual Fields Hemianopsia, Occipital Lobe Infarct, Quadrantanopsia, Stroke Hemorrhagic
Interventions
Subacute Training in the intact field, Subacute Training in the blind field, Chronic Training in the blind field
Device
Lead sponsor
University of Rochester
Other
Eligibility
21 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Jun 10, 2026, 9:20 PM EDT